Acusphere (OTCMKTS:ACUS) & Surrozen (NASDAQ:SRZN) Financial Comparison

Acusphere (OTCMKTS:ACUS) and Surrozen (NASDAQ:SRZN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Insider & Institutional Ownership

66.6% of Surrozen shares are owned by institutional investors. 4.6% of Acusphere shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Acusphere and Surrozen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acusphere	0	0	0	0	0.00
Surrozen	1	0	3	1	2.80

Surrozen has a consensus price target of $42.00, indicating a potential upside of 66.53%. Given Surrozen’s stronger consensus rating and higher possible upside, analysts clearly believe Surrozen is more favorable than Acusphere.

Earnings & Valuation

This table compares Acusphere and Surrozen”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acusphere	N/A	N/A	N/A	N/A	N/A
Surrozen	$7.49 million	39.07	-$242.03 million	($37.59)	-0.67

Acusphere has higher earnings, but lower revenue than Surrozen.

Profitability

This table compares Acusphere and Surrozen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acusphere	N/A	N/A	N/A
Surrozen	-4,810.50%	-4,055.04%	-154.08%

Summary

Surrozen beats Acusphere on 7 of the 10 factors compared between the two stocks.

About Acusphere

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.